Nutlin-3 was the first MDM2 antagonist identified that binds to the p53-binding pocket of MDM2 (IC50~90 nM) and has shown preclinical efficacy by inducing cancer cell apoptosis and reducing tumor growth in mice [124,125]. This evidence concerns the gene TP53 and neoplasm.